Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia

Differentiating agents have been proposed to overcome the impaired cellular differentiation in acute myeloid leukemia (AML). However, only the combinations of all-trans retinoic acid or arsenic trioxide with chemotherapy have been successful, and only in treating acute promyelocytic leukemia (also called AML3). We show that iron homeostasis is an effective target in the treatment of AML. Iron chelating therapy induces the differentiation of leukemia blasts and normal bone marrow precursors into monocytes/macrophages in a manner involving modulation of reactive oxygen species expression and the activation of mitogen-activated protein kinases (MAPKs). 30% of the genes most strongly induced by iron deprivation are also targeted by vitamin D3 (VD), a well known differentiating agent. Iron chelating agents induce expression and phosphorylation of the VD receptor (VDR), and iron deprivation and VD act synergistically. VD magnifies activation of MAPK JNK and the induction of VDR target genes. When used to treat one AML patient refractory to chemotherapy, the combination of iron-chelating agents and VD resulted in reversal of pancytopenia and in blast differentiation. We propose that iron availability modulates myeloid cell commitment and that targeting this cellular differentiation pathway together with conventional differentiating agents provides new therapeutic modalities for AML.

[1]  C. Felix,et al.  The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.

[2]  D. Gilliland,et al.  Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.

[3]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[4]  P. Pandolfi,et al.  Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation , 2008, Nature Medicine.

[5]  H. Kantarjian,et al.  Progress in the treatment of acute myeloid leukemia , 2007, Cancer.

[6]  Tina N. Davis,et al.  Proteomic and genetic approaches identify Syk as an AML target. , 2009, Cancer cell.

[7]  H. Mcardle,et al.  Transferrin-receptor interaction and iron uptake by reticulocytes of vertebrate animals — a comparative study , 2004, Journal of Comparative Physiology B.

[8]  A. Friedman.  Transcriptional regulation of granulocyte and monocyte development , 2002, Oncogene.

[9]  W. Faulk,et al.  TRANSFERRIN AND TRANSFERRIN RECEPTORS IN CARCINOMA OF THE BREAST , 1980, The Lancet.

[10]  B. Verhasselt,et al.  HOX-A10 regulates hematopoietic lineage commitment: evidence for a monocyte-specific transcription factor. , 2002, Blood.

[11]  N. Brousse,et al.  Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. , 2007, Cancer research.

[12]  S. Armstrong,et al.  FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress , 2007, Cell.

[13]  H. DeLuca,et al.  Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. , 1984, Cancer research.

[14]  Claudia A. Garay-Canales,et al.  1α, 25‐Dihydroxy‐vitamin D3 alters syk activation through FcγRII in monocytic THP‐1 cells , 2003 .

[15]  Xuening Wang,et al.  Jun N‐terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25‐dihydroxyvitamin D3 , 2003, Journal of cellular biochemistry.

[16]  D. Richardson,et al.  Iron trafficking in the mitochondrion: novel pathways revealed by disease. , 2005, Blood.

[17]  J. Ito,et al.  Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation , 2008, Bone Marrow Transplantation.

[18]  A. Whitmarsh,et al.  Signal Transduction by MAP Kinases: Regulation by Phosphorylation-Dependent Switches , 1999, Science's STKE.

[19]  M. Minden,et al.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia. , 2002, Blood.

[20]  V. Pullarkat.  Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? , 2009, Blood.

[21]  J. Ambrus,et al.  Effect of 1,25(OH)2 Vitamin D3 Analogs on Differentiation Induction and Cytokine Modulation in Blasts from Acute Myeloid Leukemia Patients , 2004, Leukemia & lymphoma.

[22]  J. Larghero,et al.  1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. , 2004, Molecular endocrinology.

[23]  R. Salgia,et al.  Hematopoietic growth factors signal through the formation of reactive oxygen species. , 1999, Blood.

[24]  U. Banerjee,et al.  Reactive Oxygen Species prime Drosophila haematopoietic progenitors for differentiation , 2009, Nature.

[25]  L. Zimmerman,et al.  THE COMBINED USE OF MICROINCINERATION AND THE PRUSSIAN BLUE REACTION FOR A MORE SENSITIVE HISTOCHEMICAL DEMONSTRATION OF IRON , 1964, Journal of Histochemistry and Cytochemistry.

[26]  C. Proud,et al.  Methods for studying signal-dependent regulation of translation factor activity. , 2007, Methods in enzymology.

[27]  David A. Hume,et al.  The JNK Are Important for Development and Survival of Macrophages , 2006, The Journal of Immunology.

[28]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[29]  G. P. Studzinski,et al.  Retinoblastoma Protein and CCAAT/Enhancer-Binding Protein β Are Required for 1,25-Dihydroxyvitamin D3-Induced Monocytic Differentiation of HL60 Cells , 2004, Cancer Research.

[30]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[31]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[32]  Ewa Marcinkowska,et al.  Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy. , 2010, Leukemia research.

[33]  N. Holbrook,et al.  Cellular response to oxidative stress: Signaling for suicide and survival * , 2002, Journal of cellular physiology.

[34]  D. Richardson,et al.  The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. , 1994, Cancer research.

[35]  D. Richardson,et al.  Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. , 2007, Blood.

[36]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[37]  A. Renand,et al.  Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody , 2008, Leukemia.

[38]  D. Richardson,et al.  Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. , 2009, Biochimica et biophysica acta.

[39]  C. Preudhomme,et al.  Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients , 2006, Leukemia.

[40]  T. Daniels,et al.  The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. , 2006, Clinical immunology.

[41]  W. Breuer,et al.  A review of fluorescence methods for assessing labile iron in cells and biological fluids. , 2002, Analytical biochemistry.

[42]  G. Kansas,et al.  Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. , 1990, Blood.

[43]  J. O'kelly,et al.  Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. , 2005, Leukemia research.

[44]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[45]  I. Trowbridge,et al.  Structure and function of transferrin receptors and their relationship to cell growth. , 1986, Biochemical Society symposium.

[46]  D. Mason,et al.  Transferrin receptors in human tissues: their distribution and possible clinical relevance. , 1983, Journal of clinical pathology.

[47]  M. Herlyn,et al.  Rewired ERK-JNK signaling pathways in melanoma. , 2007, Cancer cell.

[48]  M. Davies,et al.  The oxidative environment and protein damage. , 2005, Biochimica et biophysica acta.

[49]  M. Cooper,et al.  Identification of the Transferrin Receptor as a Novel Immunoglobulin (Ig)a1 Receptor and Its Enhanced Expression on Mesangial Cells in Iga Nephropathy , 2001, The Journal of experimental medicine.

[50]  L. Galluzzi,et al.  Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. , 2008, Biochemical pharmacology.

[51]  C. Preudhomme,et al.  Cooperating gene mutations in acute myeloid leukemia: a review of the literature , 2008, Leukemia.

[52]  V. Lallemand-Breitenbach,et al.  Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission , 2001, Oncogene.

[53]  D. Richardson,et al.  Potent Antitumor Activity of Novel Iron Chelators Derived from Di-2-Pyridylketone Isonicotinoyl Hydrazone Involves Fenton-Derived Free Radical Generation , 2004, Clinical Cancer Research.

[54]  I. Moura,et al.  A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients , 2004, Retrovirology.

[55]  A. Friedman.  Transcriptional control of granulocyte and monocyte development , 2007, Oncogene.

[56]  S. Fröhling,et al.  Genetics of myeloid malignancies: pathogenetic and clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Trowbridge Is,et al.  Structure and function of transferrin receptors and their relationship to cell growth. , 1986 .

[58]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[59]  M. Haussler,et al.  Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  I. Trowbridge,et al.  Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells , 1981, Nature.

[61]  J. Adamson,et al.  The relationship of erythropoietin and iron metabolism to red blood cell production in humans. , 1994, Seminars in oncology.

[62]  Z. Wang,et al.  Retinoic acid and acute promyelocytic leukemia: a model of targetting treatment for human cancer. , 1994, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[63]  D. Richardson,et al.  Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. , 2004, Blood.

[64]  D. Richardson,et al.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.

[65]  M. Konopleva,et al.  Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia , 2005, Leukemia.

[66]  N. Reiner,et al.  1α,25-Dihydroxyvitamin D3–Induced Myeloid Cell Differentiation Is Regulated by a Vitamin D Receptor–Phosphatidylinositol 3-Kinase Signaling Complex , 1999, The Journal of experimental medicine.

[67]  T. Graf,et al.  MafB Is an Interaction Partner and Repressor of Ets-1 That Inhibits Erythroid Differentiation , 1996, Cell.

[68]  B. Kalyanaraman.  Iron signaling and oxidant damage , 2007, Cardiovascular Toxicology.

[69]  M. Boccadoro,et al.  Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. , 2004, Haematologica.

[70]  Utpal Banerjee,et al.  Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint , 2008, Nature Genetics.

[71]  Gustavo Helguera,et al.  The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.

[72]  Francesco Ferrari,et al.  The Vitamin D3/Hox-A10 Pathway Supports MafB Function during the Monocyte Differentiation of Human CD34+ Hemopoietic Progenitors1 , 2008, The Journal of Immunology.

[73]  T. Graf,et al.  A transcription factor party during blood cell differentiation. , 1998, Current opinion in genetics & development.

[74]  H. Sakagami,et al.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[75]  M. Benhamou,et al.  Phospholipid Scramblase 1 Modulates a Selected Set of IgE Receptor-mediated Mast Cell Responses through LAT-dependent Pathway* , 2008, Journal of Biological Chemistry.